181 related articles for article (PubMed ID: 7981453)
1. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain.
Wolf DM; Jordan VC
Breast Cancer Res Treat; 1994; 31(1):129-38. PubMed ID: 7981453
[TBL] [Abstract][Full Text] [Related]
2. Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice.
Wolf DM; Jordan VC
Breast Cancer Res Treat; 1994; 31(1):117-27. PubMed ID: 7981452
[TBL] [Abstract][Full Text] [Related]
3. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites.
Wolf DM; Langan-Fahey SM; Parker CJ; McCague R; Jordan VC
J Natl Cancer Inst; 1993 May; 85(10):806-12. PubMed ID: 8487325
[TBL] [Abstract][Full Text] [Related]
5. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
Osipo C; Gajdos C; Cheng D; Jordan VC
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens.
Gottardis MM; Jiang SY; Jeng MH; Jordan VC
Cancer Res; 1989 Aug; 49(15):4090-3. PubMed ID: 2743303
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a point mutation in the hormone binding domain of the estrogen receptor from an breast tumor.
England GM; Bilimoria MM; Chen Z; Assikis VJ; Muenzner HD; Jordan VC
Int J Oncol; 1998 May; 12(5):981-6. PubMed ID: 9538117
[TBL] [Abstract][Full Text] [Related]
8. Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice.
Schafer JM; Lee ES; O'Regan RM; Yao K; Jordan VC
Clin Cancer Res; 2000 Nov; 6(11):4373-80. PubMed ID: 11106256
[TBL] [Abstract][Full Text] [Related]
9. Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice.
Lee ES; Schafer JM; Yao K; England G; O'Regan RM; De Los Reyes A; Jordan VC
Clin Cancer Res; 2000 Dec; 6(12):4893-9. PubMed ID: 11156249
[TBL] [Abstract][Full Text] [Related]
10. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
11. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse.
Gottardis MM; Robinson SP; Satyaswaroop PG; Jordan VC
Cancer Res; 1988 Feb; 48(4):812-5. PubMed ID: 3338079
[TBL] [Abstract][Full Text] [Related]
12. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
Morrissey JJ; Raney S
Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
[TBL] [Abstract][Full Text] [Related]
13. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
BrĂ¼nner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
[TBL] [Abstract][Full Text] [Related]
14. Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha.
Chisamore MJ; Ahmed Y; Bentrem DJ; Jordan VC; Tonetti DA
Clin Cancer Res; 2001 Oct; 7(10):3156-65. PubMed ID: 11595710
[TBL] [Abstract][Full Text] [Related]
15. Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts.
Schafer JM; Lee ES; Dardes RC; Bentrem D; O'Regan RM; De Los Reyes A; Jordan VC
Clin Cancer Res; 2001 Aug; 7(8):2505-12. PubMed ID: 11489833
[TBL] [Abstract][Full Text] [Related]
16. Human recombinant interferon-beta SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse.
Gibson DF; Johnson DA; Goldstein D; Langan-Fahey SM; Borden EC; Jordan VC
Breast Cancer Res Treat; 1993; 25(2):141-50. PubMed ID: 8347846
[TBL] [Abstract][Full Text] [Related]
17. Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro.
Gottardis MM; Wagner RJ; Borden EC; Jordan VC
Cancer Res; 1989 Sep; 49(17):4765-9. PubMed ID: 2758410
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of estrogen receptor mRNA splice variants in the tamoxifen resistant human breast cancer cell line, MCF-7/TAMR-1 compared to the parental MCF-7 cell line.
Madsen MW; Reiter BE; Lykkesfeldt AE
Mol Cell Endocrinol; 1995 Apr; 109(2):197-207. PubMed ID: 7664983
[TBL] [Abstract][Full Text] [Related]
19. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu.
Benz CC; Scott GK; Sarup JC; Johnson RM; Tripathy D; Coronado E; Shepard HM; Osborne CK
Breast Cancer Res Treat; 1992; 24(2):85-95. PubMed ID: 8095168
[TBL] [Abstract][Full Text] [Related]
20. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]